Reply to: Technical challenges of studying the impact of plasma components on the efficacy of lipid nanoparticles for vaccine and therapeutic applications

• Kai Liu,
• Elisa Lázaro-Ibáñez,
• Michael Lerche,
• Daniel Lindén,
• Anna Salvati,
• Alan Sabirsh

Affiliations

Kai Liu

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca

Elisa Lázaro-Ibáñez

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca

Michael Lerche

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca

Daniel Lindén

Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca

Anna Salvati

Department of Nanomedicine & Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen

Alan Sabirsh

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca